

REAL WORLD EXPERIENCE WITH ABEMACICLIB IN HER2 NEGATIVE ADVANCED LUMINAL BREAST CANCER: EFFECTIVENESS EVALUATION

M.I. CASTILLO MEDRANO 1, R. FERNANDEZ GALAN 1, A. FERRER PENA 1, I. BAÑEZ RIVERA 1, L.C. FERNANDEZ LISON 1.
1SAN PEDRO DE ALCANTARA HOSPITAL, HOSPITAL PHARMACY, CACERES, SPAIN.

ABSTRACT NUMBER: 4CPS-290



Background and importance

- **Abemaciclib** is a CDK4/6 inhibitor (CDKi) currently indicated for treatment of HER2 negative (HER2-) advanced luminal breast cancer (ALBC), besides adjuvant therapy.

Aim and objectives




- To evaluate abemaciclib's **effectiveness** among several indicators: objective response rate (**ORR**), duration of response (**DoR**), progression free survival (**PFS**) and overall survival (**OS**).

Materials and methods

- Design: multicentric, observational, descriptive and retrospective study.
- Inclusion criteria: Cáceres and Badajoz patients who started abemaciclib during 1/7/17-31/3/24.
- Exclusion criteria: early-stage patients starting adjuvant treatment.
- Follow-up period: from 1/7/17 to 31/3/25.
- Data: age and date at abemaciclib beginning, progression date, death date, best response reached (complete response (CR), partial response (PR)), best response date, last observation date, abemaciclib ending date.
- Data collection and processing: electronic health record, Farmatools®, Excel® and SPSS® (Kaplan-Meier test).

Results

- 64 patients met the inclusion criteria and finally **30 women** resulted after exclusion criteria applied.
- **Median age** at beginning: **59** years (interquartile range IQR:55.25-71.5).
- **PFS**: the mean was 29'8 months (95% confidence interval(CI):21'86-37'7) and **median** was **31 months** (95%CI not reached).
- **OS**: the mean was 33'8 months (95%CI:26'6-41'1) and **median wasn't reached**.
- **ORR%**(CR+PR) = **46'7%** (95%CI:30'2-63'9).
- **DoR** = **32'4 months** (95%CI:22'3-42'4).



Conclusion and relevance

Despite the limited sample size, the results suggest that **abemaciclib's effectiveness** seems **consistent** with **MONARCH-3** results:

- Median **PFS** in MONARCH-3: 28.2 months. **Our own results** are **similar**.
- Median **OS** in MONARCH-3: 66.81 months. **Our own results don't reach the median**.
- **ORR** in MONARCH-3: 49.7%. **Our own results** are **similar**.
- **DoR** in MONARCH-3: 27.4 months. **Our own results** seem to be **higher**.

